AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: BALVERSA® (erdafitinib) (balversa.com)
This is a low-BS, highly regulated pharmaceutical site that prioritizes clinical definitions over marketing hyperbole. Its score is driven not by the presence of hot air, but by the technical omission of structured data and the failure to provide direct external proof paths for its valid clinical claims.
Implement MedicalEntity and Drug schema in the JSON-LD to establish technical authority and link to the official FDA approval documents. Replace generic calls to action like See study results with specific, high-level clinical metrics such as Objective Response Rate (ORR) percentages. Provide outbound links to the specific ClinicalTrials.gov record (e.g., NCT02365597) to provide a verifiable proof path for clinical assertions. Fix the heading hierarchy on the taking-balversa sub-page to improve technical SEO and accessibility standards.
The Information Density score is low, indicating high substance. The site avoids common fluff adjectives like revolutionary or bespoke, instead using technical nouns such as kinase inhibitor and urothelial cancer. While the homepage H1 IT’S TIME TO SEE WHAT A TARGETED TREATMENT CAN DO FOR YOU uses power words, it is immediately supported by specific medical indications. However, the density is slightly reduced by the absence of specific outcome percentages (e.g., survival rates or response metrics) in the body text between headings.
If your canonical, redirect, and final URL disagree, AI cannot determine which version to trust. Verify your Identity Stability for free and detect conflicts before they fragment your authority.
There is zero semantic drift across the analyzed pages. The homepage establishes BALVERSA as a targeted treatment for FGFR-abnormal bladder cancer, and sub-pages like About Bladder Cancer and How BALVERSA Works deliver exactly on that promise without pivoting to broader or contradictory claims. The messaging is highly consistent, focusing exclusively on the identified patient population and the medication’s specific mechanism of action.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The trust_theatre_flag is false and the review_count is 0, which is appropriate for a regulated pharmaceutical product. However, the site receives a penalty in this pillar because the proof_links_count is 0 across all pages, meaning that although clinical trial results and FDA approval are mentioned, the site provides no direct external proof paths (like links to PubMed or ClinicalTrials.gov) in the crawled text. This creates a reliance on internal claims rather than verifiable external evidence.
The proof density is moderate; technical specifications like erdafitinib and FGFR gene are frequently cited, but they are not accompanied by granular data or citations. The site lists four specific proof-related topics (FDA approval, FGFR gene testing, clinical study results, side effects) but fails to provide the underlying data or external validation links for any of them. This creates a high ratio of vague assertions to verifiable evidence.
For a demonstration of entity driven retail architecture, open the Walmart Structured Data audit. View the Walmart Structured Data Audit to see how product, brand, and service entities are reconstructed for AI systems.
The site follows a standard pharmaceutical patient-education template with sections like How it Works and Taking BALVERSA. It contains several industry_jargon matches such as FDA approved, clinical trial data, and mechanism of action. Because the product is a unique, trademarked medication with a narrow therapeutic indication, the value proposition is naturally differentiated and cannot be easily applied to a competitor.
A significant authority gap exists due to the total absence of structured data (schema_json is null), which is a technical failure for a site positioned as a medical authority. There is no Person schema or sameAs links for medical experts or researchers, as the content relies on generic healthcare provider references. The technical credibility is further weakened by the broken heading hierarchy mentioned in the crawl data for the starting-balversa page.
The site makes bold claims such as being the first medicine of its kind and a targeted treatment. While these claims are supported by technical definitions of FGFR targeting, there is a disconnect because the performance results (the study results) are mentioned as a call-to-action but are not displayed as substantive metrics within the text. This results in a moderate score for substantiated claims.
Medical Devices, Pharma & Biotech BS: BALVERSA® (erdafitinib) (balversa.com)
The website perfectly aligns with the Pharma & Biotech industry category. The content is strictly focused on a prescription medication, specific genetic biomarkers (FGFR gene), and regulatory status (FDA), which are the defining characteristics of this sector.
The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.
“The score of 32 is primarily driven by the Identity and Authority pillar (due to missing schema) and the Trust and Proof pillar (due to zero external proof links). The site is largely free of Semantic Drift and Information Density fluff, which are the most common sources of high BS scores in other industries.”